PDCD1 and neoplasm: Anti-PD-1 monoclonal antibodies bind to the PD-1 receptor and prevent interactions with its ligands PD-L1 and PD-L2, thereby releasing PD-1 pathway-mediated inhibition of the immune tumor response [1].